Grace Therapeutics (GRCE) Competitors $3.29 -0.10 (-2.95%) As of 02/21/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends GRCE vs. BDTX, SAVA, TSVT, CRBU, BMEA, RENB, CHRS, SGMT, TELO, and KYTXShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Black Diamond Therapeutics (BDTX), Cassava Sciences (SAVA), 2seventy bio (TSVT), Caribou Biosciences (CRBU), Biomea Fusion (BMEA), Renovaro (RENB), Coherus BioSciences (CHRS), Sagimet Biosciences (SGMT), Telomir Pharmaceuticals (TELO), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Black Diamond Therapeutics Cassava Sciences 2seventy bio Caribou Biosciences Biomea Fusion Renovaro Coherus BioSciences Sagimet Biosciences Telomir Pharmaceuticals Kyverna Therapeutics Grace Therapeutics (NASDAQ:GRCE) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability. Which has stronger valuation & earnings, GRCE or BDTX? Grace Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$12.85M-$1.16-2.84Black Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.62 Do analysts prefer GRCE or BDTX? Grace Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 264.74%. Black Diamond Therapeutics has a consensus price target of $15.50, indicating a potential upside of 617.59%. Given Black Diamond Therapeutics' higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Grace Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in GRCE or BDTX? 6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, GRCE or BDTX? Grace Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Does the MarketBeat Community prefer GRCE or BDTX? Black Diamond Therapeutics received 50 more outperform votes than Grace Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Grace Therapeutics an outperform vote while only 69.86% of users gave Black Diamond Therapeutics an outperform vote. CompanyUnderperformOutperformGrace TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesBlack Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% Is GRCE or BDTX more profitable? Grace Therapeutics' return on equity of -20.10% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -20.10% -17.10% Black Diamond Therapeutics N/A -68.08%-49.65% Does the media favor GRCE or BDTX? In the previous week, Grace Therapeutics had 5 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 7 mentions for Grace Therapeutics and 2 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.46 beat Grace Therapeutics' score of 1.14 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGrace Therapeutics and Black Diamond Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.37M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-2.845.7326.0419.11Price / SalesN/A306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book0.646.717.644.62Net Income-$12.85M$138.33M$3.18B$245.85M7 Day Performance-4.64%-2.63%-2.00%-2.61%1 Month Performance-15.86%-2.33%-0.44%-2.14%1 Year PerformanceN/A-5.33%16.44%12.98% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.6 of 5 stars$3.29-2.9%$12.00+264.7%N/A$34.37MN/A-2.84N/AAnalyst ForecastAnalyst RevisionNews CoverageGap DownBDTXBlack Diamond Therapeutics3.3793 of 5 stars$2.37+3.9%$15.50+554.0%-53.7%$134.10MN/A-1.7890Short Interest ↓Positive NewsSAVACassava Sciences3.7747 of 5 stars$2.78+8.2%$111.50+3,910.8%-88.5%$133.75MN/A-2.0130Gap UpTSVT2seventy bio2.1861 of 5 stars$2.57+7.5%$7.20+180.2%-53.2%$132.59M$100.39M-1.38440Analyst ForecastNews CoverageCRBUCaribou Biosciences3.1342 of 5 stars$1.43+0.7%$10.33+622.6%-80.8%$129.49M$34.48M-0.87100BMEABiomea Fusion3.3309 of 5 stars$3.57-0.6%$39.36+1,002.6%-77.4%$129.38MN/A-0.8950Positive NewsRENBRenovaro0.7629 of 5 stars$0.86+5.6%N/A-61.1%$129.21MN/A-0.9020Earnings ReportNews CoverageGap UpCHRSCoherus BioSciences3.6681 of 5 stars$1.10-1.8%$5.38+388.6%-56.9%$127.48M$257.24M-13.75330SGMTSagimet Biosciences1.7999 of 5 stars$4.10+1.0%$23.00+461.0%-38.9%$125.75M$2M0.008TELOTelomir Pharmaceuticals2.2879 of 5 stars$4.21+7.4%N/A-54.8%$125.29MN/A-7.261Analyst ForecastNews CoverageKYTXKyverna Therapeutics1.1479 of 5 stars$2.89-2.7%$25.71+789.8%-89.9%$124.76M$7.03M0.0096 Related Companies and Tools Related Companies Black Diamond Therapeutics Alternatives Cassava Sciences Alternatives 2seventy bio Alternatives Caribou Biosciences Alternatives Biomea Fusion Alternatives Renovaro Alternatives Coherus BioSciences Alternatives Sagimet Biosciences Alternatives Telomir Pharmaceuticals Alternatives Kyverna Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRCE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
